knowledge -WSS

knowledge

author：hotspot 2025-09-28 04:16:44 Page View：76

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Even great ERs can’t make up for American health disparities
Next article： Duchenne breakthrough therapy leaves behind pioneering families

explore

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

FDA drug safety: Singulair case shows systemic surveillance flaws

AdobeAfteradrugentersthemarket,it’suptoFoodandDrugAdministrationregulatorstoensureitscontinuedsafety

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

What Henrietta Lacks settlement says about racism in medicine

ApaintingofHenriettaLacksHenriettaLacksHouseofHealingForwhatwouldhavebeenHenriettaLacks’103thbirthda